{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:44:17Z","timestamp":1793148257625,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Objectives: Neurosarcoidosis (NS) is a severe and infrequent complication of sarcoidosis. Available data on NS are variable. We aimed to characterize NS epidemiology, clinical and therapeutic characteristics in a well-defined cohort of NS patients. Methods: Observational population-based cohort study of 342 patients diagnosed with sarcoidosis in Northern Spain, between 1999 and 2019. Among them, those patients who fulfilled the Consortium Consensus Group diagnosis criteria for NS were included. The annual incidence between 1999 and 2019 was estimated by gender, age, and year of diagnosis. Additionally, a literature review was performed. Therapeutic efficacy was evaluated using the neurological-related extra-pulmonary physician organ severity tool (ePOST). Results: NS was diagnosed in 29 out of 342 patients with sarcoidosis (8.5%; 18 women\/11 men) with a mean age of 42.3 \u00b1 15.1 years. Most NS patients have associated systemic sarcoidosis (93.4%) mainly consisting of lung (n = 22; 75.9%), articular (n = 15; 51.7%) and\/or ocular (n = 12; 40%) involvement. The annual incidence of NS during the study period was 1.1 per 1,000,000 people. There is a linear relationship with a weak decrease in age at diagnosis over time. NS was subdivided into chronic headache (n = 11; 36.7%), cranial neuropathy (n = 7; 24.1%), myelitis (n = 4; 13.8%), peripheral neuropathy (n = 3; 10.3%), cranial neuropathy with chronic headache (n = 3; 10.3%) and aseptic meningitis (n = 2; 6.9%). Twenty-five patients (86.2%) received oral glucocorticoids (mean \u00b1 SD maximum prednisone dose 49.6 \u00b1 19.4 mg\/day). In addition, conventional immunosuppressive drugs were administered to 17 (58.6%) patients and biological therapy to 12 (41.4%) patients. After 12 months of initiating biological therapy, 14 out of 17 patients (82.4%) achieved complete remission, defined as an ePOST score of 0. Severe allergic reaction was observed in only one patient who had received treatment with both Infliximab and Adalimumab. Conclusions: The epidemiological, clinical and treatment characteristics of NS in Northern Spain are similar to that of other countries.<\/jats:p>","DOI":"10.3390\/biomedicines13061360","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:19:38Z","timestamp":1748834378000},"page":"1360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5690-5330","authenticated-orcid":false,"given":"Alba","family":"Herrero-Morant","sequence":"first","affiliation":[{"name":"Rheumatology, HUM Valdecilla, Immunopathology Group, Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla (IDIVAL), 39011 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-371X","authenticated-orcid":false,"given":"Ra\u00fal","family":"Fern\u00e1ndez-Ram\u00f3n","sequence":"additional","affiliation":[{"name":"Ophtalmology, HUM Valdecilla, Immunopathology Group, Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla (IDIVAL), 39011 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Prieto-Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Rheumatology, HUM Valdecilla, Immunopathology Group, Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla (IDIVAL), 39011 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6633","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Mart\u00edn-Varillas","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital De Laredo, 39770 Laredo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital De La Princesa, IIS-Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Rheumatology, HUM Valdecilla, Immunopathology Group, Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla (IDIVAL), 39011 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.rdc.2017.06.008","article-title":"Neurosarcoidosis","volume":"43","author":"Ungprasert","year":"2017","journal-title":"Rheum. Dis. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"ref_3","first-page":"2150","article-title":"Clinical Phenotypes of Sarcoidosis Using Cluster Analysis: A Spanish Population-Based Cohort Study","volume":"42","author":"Blanco","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cho, T.A., Bhattacharyya, S., and Helfgott, S. (2019). A Comprehenisve Guide to Immune Mediated Disorders of the Nervous System. Neurorheumatology, Springer International Publishing. Neurosarcoidosis.","DOI":"10.1007\/978-3-030-16928-2"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sambon, P., Sellimi, A., Kozyreff, A., Gheysens, O., Pothen, L., Yildiz, H., and van Pesch, V. (2022). Epidemiology, Clinical Presentation, Treatment, and Outcome of Neurosarcoidosis: A Mono-Centric Retrospective Study and Literature Review. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.970168"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s00415-021-10421-z","article-title":"Effects of Immunotherapies and Clinical Outcomes in Neurosarcoidosis: A Retrospective Cohort Study","volume":"268","author":"Arun","year":"2021","journal-title":"J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fritz, D., van de Beek, D., and Brouwer, M.C. (2016). Clinical Features, Treatment and Outcome in Neurosarcoidosis: Systematic Review and Meta-Analysis. BMC Neurol., 16.","DOI":"10.1186\/s12883-016-0741-x"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Namsrai, T., Phillips, C., Desborough, J., Gregory, D., Kelly, E., Cook, M., and Parkinson, A. (2023). Diagnostic Delay of Sarcoidosis: Protocol for an Integrated Systematic Review. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0269762"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1084","DOI":"10.1212\/NXI.0000000000001084","article-title":"Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment","volume":"8","author":"Bradshaw","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1034\/j.1399-3003.1999.14d02.x","article-title":"ATS\/ERS\/WASOG Statement on Sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Costabel","year":"1995","journal-title":"Eur. Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis Epidemiology: Recent Estimates of Incidence, Prevalence and Risk Factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"577871","DOI":"10.1016\/j.jneuroim.2022.577871","article-title":"Clinical Features and Diagnosis of Neurosarcoidosis\u2014Review Article","volume":"368","author":"Barreras","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11926-022-01089-z","article-title":"Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment","volume":"24","author":"Gosselin","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14737175.2022.2108705","article-title":"Neurosarcoidosis: An Update on Diagnosis and Therapy","volume":"22","author":"Ungprasert","year":"2022","journal-title":"Expert Rev. Neurother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.lpm.2011.12.017","article-title":"Neurosarcoidosis: Clinical Manifestations, Diagnosis and Treatment","volume":"41","author":"Nozaki","year":"2012","journal-title":"Presse Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"210165","DOI":"10.1183\/16000617.0165-2021","article-title":"WASOG Statement on the Diagnosis and Management of Sarcoidosis-Associated Pulmonary Hypertension","volume":"31","author":"Savale","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of Infliximab in Extrapulmonary Sarcoidosis: Results from a Randomised Trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-Term Outcomes of Refractory Neurosarcoidosis Treated with Infliximab","volume":"264","author":"Bouvry","year":"2017","journal-title":"J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2021.05.011","article-title":"Epidemiology of Sarcoidosis in Northern Spain, 1999\u20132019: A Population-Based Study","volume":"91","author":"Llorca","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders 3rd Edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.ejim.2011.08.019","article-title":"Neurosarcoidosis","volume":"22","author":"Murillo","year":"2011","journal-title":"Eur. J. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e3277","DOI":"10.1097\/MD.0000000000003277","article-title":"Neurosarcoidosis in a Tertiary Referral Center: A Cross-Sectional Cohort Study","volume":"95","author":"Leonhard","year":"2016","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of Prognostic Factors and Immunosuppressive Treatment With Long-Term Outcomes in Neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4103\/0028-3886.288976","article-title":"A Study of the Clinical Profile, Radiologic Features, and Therapeutic Outcomes in Neurosarcoidosis from Two Tertiary Care Centers in Southern India","volume":"68","author":"Goel","year":"2020","journal-title":"Neurol. India"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"577913","DOI":"10.1016\/j.jneuroim.2022.577913","article-title":"A Prospective, One-Year Follow-up Study of Patients Newly Diagnosed with Neurosarcoidosis","volume":"369","author":"Byg","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref_27","first-page":"25","article-title":"Neurosarcoidosis in a Public Safety Net Hospital: A Study of 82 Cases","volume":"36","author":"Dorman","year":"2019","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117073","DOI":"10.1016\/j.jns.2020.117073","article-title":"The Effect of Race on Clinical Presentation and Outcomes in Neurosarcoidosis","volume":"417","author":"Affan","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.36648\/2171-6625.10.2.292","article-title":"Clinical Manifestations of Neurosarcoidosis in the Netherlands","volume":"10","author":"Voortman","year":"2019","journal-title":"J. Neurol. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","first-page":"380","article-title":"Epidemiologic Patterns of Disease Expression in Sarcoidosis: Age, Gender and Ethnicity-Related Differences","volume":"34","author":"Bosch","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"236905","DOI":"10.1155\/2014\/236905","article-title":"Sarcoidosis: Sex-Dependent Variations in Presentation and Management","volume":"2014","author":"Birnbaum","year":"2014","journal-title":"J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00415-014-7482-9","article-title":"Overview of Neurosarcoidosis: Recent Advances","volume":"262","author":"Hebel","year":"2015","journal-title":"J. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1212\/NXI.0000000000000743","article-title":"Neurosarcoidosis: Longitudinal Experience in a Single-Center, Academic Healthcare System","volume":"7","author":"Lord","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the Treatment of CNS Sarcoidosis: A Multi-Institutional Series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e200429","DOI":"10.1212\/CPJ.0000000000200429","article-title":"Consensus Recommendations for the Management of Neurosarcoidosis A Delphi Survey of Experts Across the United States","volume":"15","author":"Levy","year":"2025","journal-title":"Neurol. Clin. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2022.11.020","article-title":"Systemic Treatment in Sarcoidosis: Experience over Two Decades","volume":"108","year":"2023","journal-title":"Eur. J. Intern. Med."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:45:27Z","timestamp":1760031927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biomedicines13061360"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13061360","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}